Piper Sandler Reiterates Overweight on Oscar Health, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jessica Tassan has reiterated an Overweight rating on Oscar Health (NYSE:OSCR) and maintained a price target of $28.
September 10, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on Oscar Health, maintaining a $28 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $28 by Piper Sandler suggests a positive outlook for Oscar Health. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100